Max Shelkrot1, Jonida Miraka2, Mirza E Perez2. 1. Medical Information Specialist, Med Communications , Wilmington, Delaware. 2. Temple University School of Pharmacy , Philadelphia, Pennsylvania .
Abstract
OBJECTIVE: To evaluate the appropriate dose of enoxaparin for venous thromboembolism (VTE) prophylaxis in patients with extreme obesity. METHODS: A literature search was performed using MEDLINE (1950-April 2013) to analyze all English-language articles that evaluated incidence of VTE and/or anti-Xa levels with enoxaparin for thromboprophylaxis in patients with extreme obesity. RESULTS: Eight studies were included in the analysis. Six of the studies were done in patients undergoing bariatric surgery. Mean body mass index ranged from 44.9 to 63.4 kg/m(2) within studies. Studies done with bariatric surgery patients utilized doses of enoxaparin that ranged from the standard dose of 30 mg subcutaneous (SQ) every 12 hours to 60 mg SQ every 12 hours. Other studies evaluated doses ranging from 40 mg SQ every 24 hours to 0.5 mg/kg/day. Only 3 studies evaluated the incidence of VTE as the primary endpoint; the other studies evaluated anti-Xa levels. The studies showed that appropriate anti-Xa levels were achieved more often with higher than standard doses of enoxaparin. One study showed that enoxaparin 40 mg SQ every 12 hours decreased the incidence of VTE in patients undergoing bariatric surgery compared to standard doses. Overall risk of bleeding was similar between study groups. CONCLUSIONS: Higher than standard doses of enoxaparin may be needed for patients with extreme obesity. Patients undergoing bariatric surgery may benefit from enoxaparin 40 mg SQ every 12 hours. Additional large randomized, controlled trials are needed to determine the efficacy and safety of higher than standard doses of enoxaparin for VTE prophylaxis in patients with extreme obesity.
OBJECTIVE: To evaluate the appropriate dose of enoxaparin for venous thromboembolism (VTE) prophylaxis in patients with extreme obesity. METHODS: A literature search was performed using MEDLINE (1950-April 2013) to analyze all English-language articles that evaluated incidence of VTE and/or anti-Xa levels with enoxaparin for thromboprophylaxis in patients with extreme obesity. RESULTS: Eight studies were included in the analysis. Six of the studies were done in patients undergoing bariatric surgery. Mean body mass index ranged from 44.9 to 63.4 kg/m(2) within studies. Studies done with bariatric surgery patients utilized doses of enoxaparin that ranged from the standard dose of 30 mg subcutaneous (SQ) every 12 hours to 60 mg SQ every 12 hours. Other studies evaluated doses ranging from 40 mg SQ every 24 hours to 0.5 mg/kg/day. Only 3 studies evaluated the incidence of VTE as the primary endpoint; the other studies evaluated anti-Xa levels. The studies showed that appropriate anti-Xa levels were achieved more often with higher than standard doses of enoxaparin. One study showed that enoxaparin 40 mg SQ every 12 hours decreased the incidence of VTE in patients undergoing bariatric surgery compared to standard doses. Overall risk of bleeding was similar between study groups. CONCLUSIONS: Higher than standard doses of enoxaparin may be needed for patients with extreme obesity. Patients undergoing bariatric surgery may benefit from enoxaparin 40 mg SQ every 12 hours. Additional large randomized, controlled trials are needed to determine the efficacy and safety of higher than standard doses of enoxaparin for VTE prophylaxis in patients with extreme obesity.
Authors: M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik Journal: Arch Pathol Lab Med Date: 1998-09 Impact factor: 5.534
Authors: Ger-Jan C M Sanderink; Colette G Guimart; Marie-Laure Ozoux; Navinchandra U Jariwala; Umesh A Shukla; Bruno X Boutouyrie Journal: Thromb Res Date: 2002-02-01 Impact factor: 3.944
Authors: A J Mayr; M Dünser; S Jochberger; D Fries; A Klingler; M Joannidis; W Hasibeder; Wolfgang Schobersberger Journal: Thromb Res Date: 2002-02-01 Impact factor: 3.944
Authors: Marilyn J Borkgren-Okonek; Robert W Hart; John E Pantano; Peter C Rantis; Paul J Guske; James M Kane; Nancy Gordon; Nancy C Sambol Journal: Surg Obes Relat Dis Date: 2008-02-08 Impact factor: 4.734
Authors: Zhamak Khorgami; Amin Andalib; Ali Aminian; Matthew D Kroh; Philip R Schauer; Stacy A Brethauer Journal: Surg Endosc Date: 2015-08-26 Impact factor: 4.584
Authors: Joseph F Rappold; Forest R Sheppard; Samuel P Carmichael Ii; Joseph Cuschieri; Eric Ley; Erika Rangel; Anupamaa J Seshadri; Christopher P Michetti Journal: Trauma Surg Acute Care Open Date: 2021-02-24